STOCK TITAN

TransCode Therapeutics Inc - RNAZ STOCK NEWS

Welcome to our dedicated news page for TransCode Therapeutics (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on TransCode Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TransCode Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TransCode Therapeutics's position in the market.

Rhea-AI Summary
TransCode Therapeutics announces underwritten public offering of common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.63%
Tags
-
Rhea-AI Summary
TransCode Therapeutics announces significantly improved survival in murine models with GBM tumors treated with TTX-MC138
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.13%
Tags
none
-
Rhea-AI Summary
TransCode Therapeutics announces preliminary results of Phase 0 clinical trial for TTX-MC138 in metastatic cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.52%
Tags
Rhea-AI Summary
TransCode Therapeutics, Inc. has closed its public offering, raising approximately $8.5 million. The funds will be used for clinical trials and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.52%
Tags
-
Rhea-AI Summary
TransCode Therapeutics, Inc. announces pricing of its public offering, expecting approximately $8 million in gross proceeds. Proceeds will be used for clinical trials and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-72.9%
Tags
-
Rhea-AI Summary
TransCode Therapeutics announces positive results with TTX-MC138 in brain cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
284.04%
Tags
none
Rhea-AI Summary
TransCode Therapeutics announces dosing of first subject in Phase 0 trial for TTX-MC138
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
-
Rhea-AI Summary
TransCode Therapeutics reports Q2 financial results and recent business progress. They have advanced their therapeutic programs, dosed their first patients in a Phase 0 clinical trial, closed a funding round of $7M, and expanded their delivery platform. They expect to achieve major milestones in the coming months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
-
Rhea-AI Summary
TransCode Therapeutics, Inc. announced positive results with its lead therapeutic candidate, TTX-MC138, in non-human primates. The study showed that TTX-MC138 effectively engaged its target, miRNA-10b, and demonstrated favorable pharmacokinetics and tissue distribution. The therapeutic showed lasting activity and significantly inhibited miRNA-10b, known to be a driver of metastatic progression in cancers. Data from the study were incorporated into a DMPK model, predicting long circulation and tissue distribution in humans. TTX-MC138 has shown complete regression of metastatic disease in mouse models and preliminary efficacy in a case study of feline mammary carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.17%
Tags
none
Rhea-AI Summary
Stonegate Healthcare Partners has released a thematic report on RNA Therapeutics, focusing on the potential of RNA therapeutics and companies leveraging RNAi technologies. The report covers over 30 companies, including Alnylam, Ionis, Laronde, TME Pharma, and Transcode Therapeutics (NASDAQ: RNAZ). It highlights innovative and undervalued companies in the field of RNA therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.71%
Tags
none
TransCode Therapeutics Inc

Nasdaq:RNAZ

RNAZ Rankings

RNAZ Stock Data

3.61M
5.81M
0.15%
0.31%
0.69%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Boston

About RNAZ

transcode therapeutics is a boston based pre-clinical biopharmaceutical company focused on discovery, development and commercialization of a pipeline of innovative microrna (mirnas or mirs) therapeutics for treating metastatic disease.